At the time of writing, Gain Therapeutics Inc [GANX] stock is trading at $2.40, up 13.74%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The GANX shares have gain 29.03% over the last week, with a monthly amount drifted -6.25%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gain Therapeutics Inc [NASDAQ: GANX] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $12. Previously, ROTH MKM started tracking the stock with Buy rating on December 06, 2024, and set its price target to $7. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $30 on April 12, 2021. BTIG Research initiated its recommendation with a Buy and recommended $30 as its price target on April 12, 2021.
For the past year, the stock price of Gain Therapeutics Inc fluctuated between $0.89 and $4.63. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Gain Therapeutics Inc [NASDAQ: GANX] shares were valued at $2.40 at the most recent close of the market. An investor can expect a potential return of 191.67% based on the average GANX price forecast.
Analyzing the GANX fundamentals
Gross Profit Margin for this corporation currently stands at 0.0% with Operating Profit Margin at -330.66%, Pretax Profit Margin comes in at -329.02%, and Net Profit Margin reading is -329.74%. To continue investigating profitability, this company’s Return on Assets is posted at -1.49, Equity is -2.04 and Total Capital is -2.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.22 points at the first support level, and at 2.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.49, and for the 2nd resistance point, it is at 2.59.
Ratios To Look Out For
It is important to note that Gain Therapeutics Inc [NASDAQ:GANX] has a current ratio of 2.99. Further, the Quick Ratio stands at 2.99, while the Cash Ratio is 2.62.
Transactions by insiders
Recent insider trading involved Mack Gene, CFO and Interim CEO, that happened on Aug 09 ’24 when 14400.0 shares were purchased. Executive Chairman, Islam Khalid completed a deal on Aug 09 ’24 to buy 50000.0 shares. Meanwhile, Director RICHMAN ERIC I bought 17000.0 shares on Jul 01 ’24.
